Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01978587 · ClinicalTrials.gov registry record · Phase 1
Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease
A Phase 1 study of Anemia in Chronic Kidney Disease, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01978587 is a Phase 1 study of Anemia in Chronic Kidney Disease that has completed, run by Akros Pharma. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01978587, a Phase 1 study of Anemia in Chronic Kidney Disease, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of hemodialysis on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety of 2 doses of JTZ-951 in subjects with end-stage renal disease (ESRD) receiving hemodialysis
Conditions Studied
Interventions
- DRUG JTZ-951
Study Locations (1)
Minnesota
- - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01978587
The ClinicalTrials.gov registry entry for NCT01978587 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anemia in Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which JTZ-951 is the first listed.
NCT01978587 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01978587 about?
NCT01978587 is a clinical study titled "Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease". The purpose of this study is to evaluate the effect of hemodialysis on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety of 2 doses of JTZ-951 in subjects with end-stage renal disease (ESRD) receiving hemodialysis
What is the current status of trial NCT01978587?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-10. Estimated completion is 2014-01.
What conditions does trial NCT01978587 study?
This clinical trial studies the following conditions: Anemia in Chronic Kidney Disease.
What interventions are being tested in trial NCT01978587?
The interventions under investigation include: JTZ-951 (DRUG).
Who is sponsoring clinical trial NCT01978587?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01978587 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.